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Background. Two years ago in this Journal, Neuhaus et
al . (1) first reported on the enhanced clinical efficacy of a
" ftontdnaded," accelerated regimen of recombinant tissue-
type plasminogen activator (rt-PA) in the treatment of pa-
tients with acute myocardial infarction . This regimen differs
from the standard regimen of rt-PA in several aspects, as
summarized in Table I . In terms of clinical efficacy, defined
as angiographic potency at 90 min, the accelerated regimen
offers nearly a 20% improvement over the standard regimen
(2) . In the earlier report of Neuhaus et al . (I) and in the
rt-PA-APSAC lanisoylated plasminogen activator complex]
Patency Study (TAPS) trial reported in this issue (3), the
accelerated regimen provided 90-min potency rates >80%, a
value that would probably approximate the optimal expected
rate of thrombolysis, given that thrombi are identified in 80%
to 97% or patients with acute myocardial infarction (4) .
It is appropriate that the dosage, rate and profile of
administration of rt-PA (and of other thrombolytic agents)
are now undergoing continued study and refinement . Em-
piriC considerations played an important role in the original
design of ri-PA dosing schedules and clinical experience,
rather than prospectively designed trials, has contributed
importantly to the development of the standard 3-h rt-PA
regimen (5,6) . in fact, the currently recommended dosage
schedule was detc.edned after higher doses (mat is, 150 mg)
were associated with an unacceptably high rate of intracere .
brat hemorrhage (6,7) .
The present study. Tanswell et al . (8) in this issue of the
journal now provide a rational pharmacokinctic explanation
for the enhanced efficacy of the front-loaded accelerated
rt-PA dosing schedules. rt-PA is a glycoprotein with a
molecular weight of approximately 70,000 d . It is glycosy-
lated in up to three sites, one of which is a high manttose-
'Editorials published in Journal of the American College ofCmdiology
reflect the views of the authors and do not necessarily represent the views of
JACC or the A .^,cdcan College of Cardiology,
From the Depanment or Medcine, Brigham end Women's Hospital and
Harvard Medical School, Buatoa, Nlassachnseus
Address far reprints : Eugene Bmunwald, Mit, Brigham and Women's
Hospital, 75 Francis Street, noston . Massachusetts 02115 .
®1992 by the Amon as College orCurdiology
JACC Vol . 19. No 5
April 19921076-e
type oligosaccharide (9) . The hepatic-medimed clearance of
rl-PA from plasma is quite rapid, with an initial plasma
half-time previously reported to be -4 min (t0) . The rapid
clearance of n-PA from plasma by the liver appears to be
mediated by two mechanisms: I) a specific uptake system on
hepatic parenchymal cells, and 2) a mannose-specific uptake
system on hepatic endothelial and Kupffer cells (11) . How-
ever, despite the short plasma half-life of rt-PA, there is
evidence that fibrinolytic activity continues for hours after
the administration of the drug, presumably because of its
activity at the thrombus (12) and the release into the circu-
lation of rt-PA initially bound to the endothelial surface (13) .
In the present stud ; on kinetics of the front-loaded
accelerated regimen, plasma rt-PA antigen concentration
reached a maximum of 4 tag/ml after the bolus injection and
plasma levels >3 ag/ml were maintained daring the lot 30
min . These latter values are approximately 30% to 50%
higher than the plasma rt-PA levels obtained with the stan-
dard dosage regimen (14,15) . In comparison, single bolus
injections of rt-PA resulted in mean peak rt-PA Concentra-
tions that are even higher (9 .8 ng/ml) (16) . These values of
circulating rt-PA are 30 to 100 times higher than the plasma
levels of plasminogen activator inhibitor-I (PAI-1) in plasma .
Levels of this magnitude should further diminish or even
render negligible any attenuating effects of PAW on rt-PA
activity (17) and may contribute to ttte improved patency
rates reported with front-loaded accelerated infusions .
The derived pharmacukinetic variables for the front-
loat!ed accelerated regimen of rt-PA are nearly identical with
previously published values for the standard regimen (9),
indicating that the hepatic rt-PA clearance mechanism or
mechanisms have the capacity to deal with the elevated
plasma levels that accompany the front-loaded regimen .
Despite the increased plasma levels of rt-PA produced by the
front-loaded regimen, the systemic effects of the enzyme, as
measured by decrements in circulating levels of fibrinogen,
plasminogen and alpha 2-antiplasmin, are similar to those
obtained with the standard dosage regimen (14) . This finding
confirms that rt-PA is a fibrin-specific agent and a relatively
inefficient activator of circulating plasminogen (17) .
Implications. The present study (8), together with the
earlier article (1) describing the improved efficacy of a
front-loaded accelerated regimen of rt-PA, indicates that the
pharmacokinetic properties of rt-PA can be expected to yield
an agent with nearly optimal lhrombulytic properties for
both the achievement of maximal early patency rates and
limited systemic plasminogen activation and fibrinogen
breakdown . One can reasonably argue that the front-loaded
accelerated regimen should supplant the standard regimen in
patients who are designated to receive rl-PA . However, it
remains to be seen if the accelerated regimen, which appears
to exploit some of the most desirable properties of rt-PA on
a theoretic basis (18), will have any additional impact on
survival . The ongoing GUSTO and Thrombolysis in Myo-
cardial Infarction (TIMI-4) trials, which are designed to
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Table 1 . rt-PA Dosage Regimens for Acute Myocardial Infarction
Tarot Dram
	
Dolor no,, Borne. Time
Regimen (mg) (mgt ih)
Standard Ilrl In 3
Front-loaded .
100 15 1,5
accelerated
n-PA = recombinant dss¢-type plasmloogea amrva,or
e cwCtpare the front-loaded accelerated rt-PA regimen with the
standard streptokinase and APSAC regimens and with the
combination of two thrombolytc agents, should be very
informative in clarifying the desirable properties of an opti-
mal thrombolytic regimen .
Thrombolytk therapy of acute myocardial infarction has
now been under inleasise investigation for a decade . Its
immediate goal is to reestablish patency efthe infarct-related
artery as rapidly as possible and to maintain its patency
without causing serious bleeding. Although the effectiveness
of this mode of therapy in reducing mortality has been well
established {19), there is no consensus regarding the optimal
thrmboiytic agent, much less the optimal dose or the
scheme of administration . There is evidence that n-PA is
more effective than streptokinase in early opening of oc .
eluded coronary arteries (5), especially when administered in
a front-beaded, accelerated regimen but reocclusion
remains a problem . Whether this improved pharmacologic
action can be translated into improved patient survival is still
unresolved. Although reocchminn can be reduced by pro-
longed infusie-s of ri-PA (20,21), the increased time appears
to be assoeialCd with an increased risk of serious bleeding
(22).
The future. An important goal in improving the care of
patients with acute myocardial infarction during the next
decade will be to optimize thrombolytic therapy .
It
is possi-
ble that a "one-two punch" consisting of a frost-loaded
accelerated regimen of rt-PA, such as that developed by
Neuhaus et al . (1) and Studied by Tanswell et al . (8),
followed by the infusion or injection of a more slowly acting,
nonfibrin-specific agent to help sustain patency, as is being
tested in TIM(-4 with anistreplase and in GUSTO with
streptokiaise, will prove to be advantageous . The incidence
of serious bleeding, the principal risk of thrombolytic ther-
apy, appears to be dose dependent, at least insofar as n- PA
is concerned (5,6) and is related, albeit in a complex fashion,
to baseline risk factors such as age, hypertension, gender
ad perhaps body size . The potential benefit of thrombolytic
therapy varies even more widely than the risk and is a
complex function of baseline left ventricular fashion, the size
and location of the jeopardized myocardium and the time
interval between the onset of symptoms and treatment.
Optimal thrombolytic therapy will probably not be identical
for all patients but will require a judicious balance between
risk and benefit . Thus, the optimal dose of one or more
thrombolytic agents is likely to be lower in a small (40 kg)
80-ymr-old woman with borderline hypertension and evi-
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deuce of a modest-size inferior-wall infarct
who is seen 4 6
after the onset of chest pain (relatively high risk"iow poten-
tial benelill than in a younger (45year old), 100-kg man
without a history of hyperteosion who is seen I b after the
onset of a large anterior wall infarct (relatively low rislalhigh
potential benefit) .
When the dust settles . there will probably not he a single
standard thrombolytic regimen (such as 100 mg of rt-PA for
3 h . 1 .5 mU of streptokinase for I h or a 30-mg bolus of
anistreplase) for all patients with evolving myocardial infarc-
tion but rather a regimen that is tailored to the individual
patient. Therefore. detailed pharmacokinetic studies, such
as those presented by Tanswell et al . (8), may contribute
importantly to optimizing thrombolytic therapy .
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